InvestSMART

ResMed Inc. (ASX: RMD) - ETF Exposure

Current share price for RMD : $35.500 0.09 (0.25%)+

ResMed Inc (RMD) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It works to increase awareness of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company provides diagnoses and develops treatments for these conditions for people worldwide.

RMD General Information +

ASX Code RMD
Website N/A
Industry/Sector Health Care Equipment
Market Cap ($M) 19,860
RMD Share Price $35.500
Day High $35.590
Day Low $35.030
Last Close $35.590
RMD Share Price Movement $0.09 ( 0.25% )
Prices as at 16:40, 18 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to RMD

As one of Australia's largest companies by market capitalisation, RMD is held across 34 ETFs spanning strategies that include health care equipment exposure . Its weighting in those funds means performance can have an outsized influence - when RMD moves, funds like LNYN, XX20, AEAE, INIF and INES that hold it can move with it.

For more concentrated exposure, ETFs such as LNYN (Lanyon Investment Fund Active ETF) allocate about 5.9% to RMD , while the average exposure across all 34 ETFs that hold it is around 2.1% .

Top ETF holdings

Last updated: ETF data and holdings as at 17 November 2026

Own RMD directly or through an ETF?

How does holding ResMed Inc. (RMD) shares directly compare to ETFs that include it?

RMD Direct
LNYN
ASX
XX20
ASX
AEAE
CBOE
INIF
ASX
INES
ASX
Holdings 1 company 40 holdings 29 holdings 35 holdings 21 holdings 22 holdings
RMD Weight 100% 5.9% 5.5% 5.4% 4.9% 4.6%
Diversification Single Stock Broad Broad Broad Broad Broad
Annual Cost Brokerage only 1% p.a. 0.75% p.a. 0.69% p.a. 0.97% p.a. 0.97% p.a.
Approx. Yield 1.2% 1.02% 1.49% - 11.82% 7.86%
Star Ratings - starstarstar star star star star

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not RMD's direct yield. Annual cost uses each ETF's MER.

RMD Exposure on $10,000 investment

How a $10,000 investment in ResMed Inc. (RMD) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
ResMed Inc. (RMD) Direct share $35.500 4.01% +$401 $10,401
Lanyon Investment Fund Active ETF (LNYN) Equity - Global Strategy $1.865 -4.36% -$436 $9,564
First Sentier EX-20 Australian Share Active ETF (XX20) Equity - Australia Strategy $1.290 0% $0 $10,000
Australian Ethical High Conviction Fund - Active ETF (AEAE) Equity - Australia Strategy $9.980 -1.48% -$148 $9,852
Intelligent Investor Aus Equity Income Fund (Managed Fund) (INIF) Equity - Australia Strategy $2.760 -2.13% -$213 $9,787
Intelligent Investor Ethical Share Fund (Managed Fund) (INES) Equity - Australia Strategy $3.370 -2.32% -$232 $9,768

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

ResMed Inc. (RMD) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Result 6.79¢ 0% 11 Nov 2026 17 Dec 2026 - - -
HFResult 6.5¢ 0% 19 Aug 2026 24 Sep 2026 - - -
Result 5.82¢ 0% 13 May 2026 18 Jun 2026 - - -

See all dividends from ResMed Inc. (RMD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

ResMed Inc. (RMD) price-sensitive announcements

RMD - Resmed Form 10-Q Quarterly Report
ResMed Inc.’s Form 10-Q for the quarter ended September 30, 2026 reports first-quarter fis
ResMed Inc. (RMD)
2 Nov 2026 | 8:13 AM
RMD - Deferral of Conversions Announcement
On 30 October 2026, ResMed Inc announced a deferral of conversions between its Australian
ResMed Inc. (RMD)
30 Oct 2026 | 11:14 AM
RMD - Dividend/Distribution - RMD
ResMed Inc announced a new ordinary quarterly dividend/distribution for ASX-listed RMD CDI
ResMed Inc. (RMD)
30 Oct 2026 | 8:13 AM
RMD - Resmed Announces Results for the First Quarter of Fiscal 202
ResMed announced first-quarter fiscal year 2027 results for the quarter ended 30 September
ResMed Inc. (RMD)
30 Oct 2026 | 8:12 AM

ResMed Inc. (RMD) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $19,860 Update - Dividend/Distribution - RMD 17 Nov 2026 8:26AM $35.200 $35.500 risen by 0.85%
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $19,860 Statement of changes in beneficial ownership 16 Nov 2026 8:13AM $34.960 $35.500 risen by 1.54%
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $19,860 Statement of changes in beneficial ownership 16 Nov 2026 8:13AM $34.960 $35.500 risen by 1.54%
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $19,860 Statement of changes in beneficial ownership 16 Nov 2026 8:12AM $34.960 $35.500 risen by 1.54%
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $19,860 Statement of changes in beneficial ownership 16 Nov 2026 8:12AM $34.960 $35.500 risen by 1.54%
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $19,860 Statement of changes in beneficial ownership 16 Nov 2026 8:12AM $34.960 $35.500 risen by 1.54%

RMD Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026F $2,235.46 $151.45 10.20% 25.03 44.61 1.18% 0.0%
2025F $2,028.91 $137.46 16.70% 27.58 34.38 0.91% 0.0%
2024A $1,737.52 $117.75 23.10% 23.39 30.04 1.09% 0.0%

RMD Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 F 2026 F 2024 A 2025 F 2026 F 2024 A 2025 F 2026 F
Cochlear Limited (COH) $9,864M -0.3136 0.2540 0.0785 36.7206 29.2828 27.1516 2.29% 2.38% 2.59%
Fisher & Paykel Healthcare Corporation Limited (FPH) $23,272M 0.1388 0.1465 0.1573 59.8216 52.1762 45.0826 1.10% 1.19% 1.32%
Imricor Medical Systems Inc (IMR) $482M -0.4254 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
ResMed Inc. (RMD) $19,693M 9.5922 0.1126 0.0881 22.8557 20.5427 18.8801 1.02% 1.08% 1.16%

RMD Directors

Name Position Start Date
Mr Michael J Farrell Chief Executive Officer, Executive Director 1 Mar 2013
Mr Ronald R Taylor Non-Executive Director 25 Jan 2005
Ms Carol Burt Non-Executive Director 11 Aug 2014
Ms Karen Ruth Drexler Non-Executive Director 17 Nov 2017
Mr Jan De Witte Non-Executive Director 16 May 2019
Ms Harjit Gill Non-Executive Director 15 Nov 2018
Dr John Hernandez Non-Executive Director 19 Nov 2021
Dr Desney Tan Non-Executive Director 19 Nov 2021
Mr Christopher DelOrefice Non-Executive Director 19 Aug 2024
Ms Nicole Mowad Nassar Non-Executive Director 15 Aug 2025
Dr Peter Craig Farrell Non-Executive Director, Non-Executive Chairman 1 Jul 2002

ResMed Inc. (RMD) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
2 Jul 2024 ROBERTS, Christopher Issued Options 12,000 $50.950 $611,400.000
19 Aug 2011 FARRELL, Peter Sell Direct Shares 200,000 $0.000
17 Aug 2011 FARRELL, Peter Issued Related Securities 28,571 $0.000

See all changes in directors' interest & trades for ResMed Inc. (RMD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RMD Management

Name Position
Aaron Bloomer CFO (Principal Financial Officer and Principal Accounting Officer)

RMD Calendar of Events

Date Event
17 December 2026 Div Pay Date

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.